Vascular Investigation and Therapy

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 1  |  Issue : 1  |  Page : 14--23

Autologous tissue patches acquire vascular identity depending on the environment


Hualong Bai1, Jianming Guo2, Shirley Liu2, Xiangjiang Guo2, Haidi Hu2, Tun Wang2, Toshihiko Isaji2, Shun Ono2, Bogdan Yatsula2, Ying Xing3, Alan Dardik4,  
1 Department of Vascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China; Department of Vascular and Endovascular Surgery, Yale University School of Medicine, CT, USA; Department of Physiology, Basic Medical College of Zhengzhou University, Henan, China
2 Department of Vascular and Endovascular Surgery, Yale University School of Medicine, CT, USA
3 Department of Physiology, Basic Medical College of Zhengzhou University, Henan, China
4 Department of Vascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China; 4Department of Surgery, VA Connecticut Healthcare System; Yale University School of Medicine, CT, USA

Correspondence Address:
Alan Dardik
Yale University School of Medicine, 10 Amistad Street, Room 437, PO Box 208089, New Haven, CT 06520-8089, USA

Abstract

Background: Vascular identity is genetically determined but can be altered during surgical procedures. Methods: We hypothesized that the environment of the procedure critically alters the identity of autologous tissue patches implanted into the arterial or venous environment. Results: Autologous jugular vein or carotid artery was used as a patch to repair a rat aorta or inferior vena cava. In the aortic environment, patches contained neointimal cells that were CD34/ephrin-B2-dual positive but not CD34/Eph-B4-dual positive; patches expressed ephrin-B2, notch-4, and dll-4 but not Eph-B4 and COUP-TFII. In the venous environment, patches contained neointimal cells that were CD34/Eph-B4-dual positive but not CD34/ephrin-B2-dual positive; patches expressed Eph-B4 and COUP-TFIIbut not ephrin-B2, notch-4, and dll-4. Conclusion: These data show that autologous tissue patches heal by acquisition of the vascular identity determined by the environment into which they are implanted, suggesting some plasticity of adult vascular identity.



How to cite this article:
Bai H, Guo J, Liu S, Guo X, Hu H, Wang T, Isaji T, Ono S, Yatsula B, Xing Y, Dardik A. Autologous tissue patches acquire vascular identity depending on the environment.Vasc Invest Ther 2018;1:14-23


How to cite this URL:
Bai H, Guo J, Liu S, Guo X, Hu H, Wang T, Isaji T, Ono S, Yatsula B, Xing Y, Dardik A. Autologous tissue patches acquire vascular identity depending on the environment. Vasc Invest Ther [serial online] 2018 [cited 2022 Aug 19 ];1:14-23
Available from: https://www.vitonline.org/text.asp?2018/1/1/14/236296


Full Text

 Introduction



Patch angioplasty is a common procedure to close medium diameter vessels, such as the carotid or femoral arteries, after a longitudinal arteriotomy; commonly used patches include autologous vein or artery as well as synthetic patches.[1],[2],[3] Future materials may include novel tissue engineered patches.[4] Despite decades of use, the mechanisms of patch healing are not well established. Using a rat aorta and inferior vena cava (IVC) angioplasty model,[5] we found that pericardial and polyester patches heal by infiltration of endothelial progenitor cells and neointimal endothelialization.[6],[7],[8]

The role of vascular identity in healing after vascular procedures is becoming more well described; for example, in vein grafts, expression of Eph-B4 is lost and expression of ephrin-B2 is not strongly induced, suggesting loss of venous identity.[9] Interestingly, in arteriovenous fistulae, the outflow vein expresses both Eph-B4 as well as ephrin-B2, that is it acquires both arterial and venous identities.[10] After pericardial or polyester patch angioplasty, these acellular patches gain either arterial or venous identity based on the location of implantation; patches implanted into the arterial environment acquire arterial identity, whereas patches implanted into the venous environment acquire venous identity.[6],[7],[8] Interestingly, prosthetic patches in the venous environment exposed to an arteriovenous fistula acquire dual arterial-venous identity and suggest plasticity of implant identity in adults undergoing vascular surgery.[8]

Despite the common use of prosthetics in vascular surgery, including the use of prosthetics for patch angioplasty, autologous tissue remains the gold standard for vessel closure and conduits. For example, saphenous vein grafts are commonly used for cardiac and peripheral bypass due to superior patency compared to prosthetic grafts.[11],[12] Similarly, in cardiac surgery, internal mammary and radial arteries are used even in preference to vein bypass.[13],[14],[15] In addition, the use of autologous vein patches is associated with superior results compared to prosthetic patches in some studies.[2],[16],[17] We hypothesized that autologous tissue patches also acquire the identity of the environment into which they are implanted. We used the rat patch angioplasty model, implanting autologous jugular vein (JV) or carotid artery (CA) patches into the aorta or the IVC to determine whether the implanted patches acquire arterial markers in the arterial environment or venous markers in the venous environment.

 Materials and Methods



Animal model

Male Wistar rats (6–8 weeks) were used for patch implantation (n = 90). The aorta or IVC was exposed, and arteriotomy or venotomy was made as previously described.[6] The arteriotomy or venotomy was closed by running suture in the direct suture (DS) group using 10-0 suture. In the patch groups, the right JV or the right CA was harvested from the same rat and trimmed to approximately 1.5 mm × 4 mm; the arteriotomy or venotomy was closed with a JV or CA patch using running 10-0 nylon suture [Supplementary Figure 1]. Rats were sacrificed after 5 min of surgery (day 0) or on postoperative day 14. No immunosuppressive agents, antibiotics, antiplatelet agents, or heparin were given at any time. All experiments were approved by the Institutional Animal Care and Use Committee at the Yale University School of Medicine.[INLINE:1]

Histology

Rats were anesthetized with isoflurane inhalation, and tissues were fixed by transcardial perfusion of phosphate-buffered saline followed by 10% formalin. Tissue was removed and fixed overnight in 10% formalin followed by a 24 h immersion in 70% alcohol, then embedded in paraffin and sectioned (5 μm thickness). Slides were de-paraffinized and stained with elastin van Gieson staining kit (Elastic stain kit, DAKO). Neointimal thickness was determined using the mean of measurements from the lumen surface edge to the edge of the patch in three independent areas, as previously described.[4]

Immunohistochemistry

Tissue sections were de-paraffinized and then incubated using primary antibodies overnight at 4°C. After overnight incubation, the sections were incubated with EnVision reagents or proper secondary antibody for 1 h at room temperature and treated with Dako Liquid diaminobenzidine (DAB) Substrate Chromogen System (Dako). The sections were then counterstained with Dako Mayer's Hematoxylin.

Immunofluorescence

Tissue sections were de-paraffinized and then incubated with primary antibodies overnight at 4°C. Sections were then treated with secondary antibodies at room temperature for 1 h. Sections were stained with SlowFade ® Gold Antifade Mountant with 4',6-diamidino-2-phenylindole (DAPI) (Life Technologies) and a coverslip applied. Digital fluorescence images were captured and intensity of immunoreactive signals was measured using ImageJ software (National Institute of Health, Bethesda, Maryland, USA).

Western blot

Patches were carefully harvested and removed from surrounding tissue and snap frozen in liquid nitrogen. Samples were crushed and mixed with buffer including protease inhibitors (Roche, Complete Mini 12108700) before sonication (5 s) and centrifugation (135,000 rpm, 15 min). Equal amounts of protein from each experimental group were loaded for SDS-PAGE, followed by Western blot analysis with signals detected using the enhanced chemiluminescence detection reagent. Patches were analyzed individually, without combination of samples.

RNA extraction and quantitative polymerase chain reaction

Total RNA from the aorta or IVC or excised patch was isolated using the RNeasy Mini kit. Reverse transcription was performed using the SuperScript III First-Strand Synthesis Supermix (Invitrogen, Carlsbad, CA, USA). Real-time quantitative polymerase chain reaction (PCR) was performed using SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) and amplified for 40 cycles using the iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories). Primers are listed in [Table 1] and their efficiencies were determined by melt curve analysis. All samples were normalized by GAPDH RNA amplification.{Table 1}

Primary and secondary antibodies

Primary antibodies included: anti-α-actin (Abcam, ab5694; IHC and IF, 1:100); anti-CD34 (R and D, AF4117; IF, 1:100); anti-CD68 (ED1; Abcam, ab31630; IHC, 1:100; IF, 1:50); anti-COUPTFII (Novus Biologicals, NBP1-67885; IHC, 1:100), anti-dll-4 (Santa Cruz, sc-18640; IHC, 1:50), and anti-Eph-B4 (Santa Cruz, sc-5536; IF, 1:50); anti-ephrin-B2 (Santa Cruz, sc-1010; IF, 1:50); anti-GAPDH (Cell Signaling, 14C10; WB, 1:2000); and anti-notch-4 antibody (Santa Cruz, SC5594; IHC, 1:50); secondary antibodies used for IF were donkey anti-goat Alexa-Fluor-488, donkey anti-rabbit Alexa-Fluor-488, donkey anti-rabbit Alexa-Fluor-568, donkey anti-mouse Alexa-Fluor-568, and chicken anti-mouse Alexa-Fluor-488 conjugated antibodies from Invitrogen (1:500). For IHC, sections were incubated with EnVision reagents for 1 h at room temperature and treated with Dako Liquid DAB + Substrate Chromogen System (Dako). Finally, the sections were counterstained with Mayer's hematoxylin.

Statistical analysis

Data are expressed as the mean ± standard error of the mean. Statistical significance for these analyses was determined using ANOVA and Tukey's multiple comparisons test for post hoc testing and t-tests as appropriate (Prism 6; GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered statistically significant.

 Results



Since prosthetic patches acquire vascular identity depending on their environment, we determined the vascular identity of autologous tissue patches used to close arteriotomies. Control aortae were directly closed with sutures, without any patch implantation; DS closure showed thin neointima covering the luminal side of the arteriotomy [day 14; [Figure 1]a and [Figure 1]b; there was no aneurysm formation, and no significant difference of the luminal area compared to day 0 [Figure 1]a. Closure of the aortic arteriotomy with an autologous JV patch resulted in patch dilation and thickening (day 14), with a thick neointima on the luminal side of the JV patch [Figure 1]a and [Figure 1]b; both the overall thickness of the JV patch and the luminal area became significantly larger at day 14 compared to day 0 [Figure 1]c and [Figure 1]d. Closure of the arteriotomy with an autologous CA patch showed patch and neointimal thickening without any luminal dilation or degradation of elastin [Figure 1]a, [Figure 1]b, [Figure 1]c, [Figure 1]d. The thickness of neointima that formed on the jugular patch was significantly greater than that which formed on the closure with either DS or a CA patch [Figure 1]b, which corresponded to a similarly greater number of α-actin-positive cells in arteries closed with JV patches [Figure 1]a. Similarly, there were greater number of CD68+ cells present in JV patches [Supplementary Figure 2]a and [Supplementary Figure 2]b. The larger number of CD68+ cells in JV patches was CD68/TGM2-dual-positive cells as well as CD68/IL10-dual-positive cells, consistent with M2type macrophages; there were also a smaller number of CD68/iNOS-dual-positive cells, as well as CD68/TNF-α-dual-positive cells, consistent with M1 type macrophages [Supplementary Figure 2]d, [Supplementary Figure 2]e, [Supplementary Figure 2]f, [Supplementary Figure 2]g, [Supplementary Figure 2]h. CD34/VEGFR2-dual positive cells, for example, endothelial progenitor cells, were present on the neointimal surface [Figure 1]e; interestingly, all patches contained neointimal cells that were CD34/ephrin-B2-dual positive but not CD34/Eph-B4-dual positive [Figure 1]e, [Figure 1]f, consistent with the presence of arterial progenitor cells in healing aortae regardless of the type of closure or patch.{Figure 1}[INLINE:2]

Tissue patches gain arterial identity in the arterial environment

Since these data suggest that closure of an arteriotomy with an autologous tissue patch may acquire arterial identity, we next determined whether the type of patch closure, for example, autologous arterial or venous patch, played a role in the type of identity that was formed. In control aortae directly sutured closed, there was no difference in ephrin-B2 or Eph-B4 transcript numbers at day 0 and 14 [Figure 2]a. In aortae closed with JV patches, there were decreased numbers of Eph-B4 transcripts and increased ephrin-B2 transcripts in the patch at day 14 compared to day 0 [Figure 2]b; however, there were no changes in transcript numbers in CA patches [Figure 2]c. Similarly, there was increased ephrin-B2 and decreased Eph-B4 protein expression in JV patches but not in CA patches or in aortae directly sutured [Figure 2]d, [Figure 2]e, [Figure 2]f. Immunofluorescence was used to determine the expression of ephrin-B2 and Eph-B4 in the neointima; in control vessels, ephrin-B2 was predominantly expressed in native arterial endothelial cells, whereas Eph-B4 was predominantly expressed in native venous endothelial cells [Figure 2]g, first and second columns]. However, by day 14, neointimal endothelial cells expressed ephrin-B2 with only weak expression of Eph-B4 regardless of the type of patch; there were a small number of α-actin/ephrin-B2-dual positive neointimal cells in all patches [Figure 2]g. Quantification of ephrin-B2 immunoreactivity in the neointimal endothelial cells showed no significant differences between patches, with similar ephrin-B2 immunoreactivity in the patches compared to the native aorta and the directly sutured aorta but significantly higher than in the native JV [Figure 2]h.{Figure 2}

We confirmed these data using the arterial markers notch-4 and dll-4 and the venous marker COUP-TFII; there were increased numbers of dll-4 and notch-4 transcripts and decreased numbers of COUP-TFII transcripts in JV patches without any changes in CA patches or in aortae directly sutured [day 14, [Figure 3]a, [Figure 3]b, [Figure 3]c. Control arteries showed notch-4 and dll-4 immunoreactivity in endothelial cells, whereas COUP-TFII immunoreactivity was present in venous endothelial cells [Figure 3]d, first and second columns]. At day 14, neointimal endothelial cells showed notch-4 and dll-4 immunoreactivity but without detectable COUP-TFII immunoreactivity [Figure 3]d; quantification showed similar notch-4, dll-4, and COUP-TFII immunoreactivity in JV and CA patches compared to the native aorta and directly sutured aortae [Figure 3]e, [Figure 3]f, [Figure 3]g, that is strong ephrin-B2, notch-4, and dll-4 and weak Eph-B4 and COUP-TFII immunoreactivity in patches used to close an artery, regardless of the source of the patch. These data suggest that arterial patches placed into the arterial environment retain their arterial identity, but venous patches lose venous identity and gain arterial identity in the arterial environment.{Figure 3}

Tissue patches gain venous identity in the venous environment

Since these data show that tissue patches acquire arterial identity when placed into the arterial environment, regardless of whether the patch was originally arterial or venous, we examined whether tissue patches gain venous identity when placed into the venous environment. Control vena cavae were directly closed with sutures, without any patch implantation; DS closure showed thin neointima covering the luminal side of the venotomy [day 14; [Figure 4]a and [Figure 4]b; there was no significant difference of the luminal area compared to day 0 [Figure 4]d. Closure of the venotomy with a JV patch resulted in a small amount of patch thickening (day 14), with some neointima on the luminal side of the JV patch [Figure 4]a, [Figure 4]b, [Figure 4]c; however, there was no significant dilation or increase in luminal area [Figure 4]a and [Figure 4]d. Closure of the venotomy with a CA patch showed a small amount of patch and neointimal thickening without any luminal dilation [Figure 4]a, [Figure 4]b, [Figure 4]c, [Figure 4]d. The thickness of neointima that formed on the patches was not significantly different than that which formed on the closure with DS [Figure 4]b, which corresponded to the lack of increased number of α-actin-positive cells in the patches [Figure 4]a. There were a similar number of CD68+ cells present in JV and CA patches as in the DS veins [Supplementary Figure 2]a and [Supplementary Figure 2]c, although the few number of CD68-positive cells were not identifiable as either M1 or M2 type [Supplementary Figure 2]d, [Supplementary Figure 2]e, [Supplementary Figure 2]f, [Supplementary Figure 2]g, [Supplementary Figure 2]h. CD34/VEGFR2-dual-positive cells, for example, endothelial progenitor cells, were present on the neointimal surface [Figure 4]e, and all patches contained neointimal cells that were CD34/Eph-B4-dual positive but not CD34/ephrin-B2-dual positive [Figure 4]e, [Figure 4]f, consistent with the presence of venous progenitor cells in healing vena cavae regardless of the type of closure or patch.{Figure 4}

In control vena cavae directly sutured closed, there was no difference in Eph-B4 or ephrin-B2 transcription numbers at day 0 and 14 [Figure 5]a. In vena cavae closed with JV patches, there were also no changes in Eph-B4 or ephrin-B2 transcript numbers [Figure 5]b; however, in CA patches, there were increased numbers of Eph-B4 transcripts and decreased ephrin-B2 transcripts at day 14 compared to day 0 [Figure 5]c. Similarly, there was increased Eph-B4 and decreased ephrin-B2 protein expression in CA patches but not in JV patches or in vena cavae directly sutured [Figure 5]d, [Figure 5]e, [Figure 5]f. Immunofluorescence was used to determine the expression of Eph-B4 and ephrin-B2 in the neointima; in control vessels, Eph-B4 was predominantly expressed in native venous endothelial cells, whereas ephrin-B2 was predominantly expressed in native arterial endothelial cells [Figure 5]g, first and second columns]. However, by day 14, neointimal endothelial cells expressed Eph-B4 with only weak expression of ephrin-B2 regardless of the type of patch; there were a small number of α-actin/Eph-B4-dual-positive neointimal cells in all patches [Figure 5]g. Quantification of Eph-B4 immunoreactivity in the neointimal endothelial cells showed no significant differences between patches, with similar Eph-B4 immunoreactivity in the patches compared to the native vena cava and the directly sutured vena cava but significantly higher than in native artery [Figure 5]h.{Figure 5}

We confirmed these data using the venous marker COUP-TFII and the arterial markers notch-4 and dll-4; there were decreased numbers of dll-4 and notch-4 transcripts and increased numbers of COUP-TFII transcripts in CA patches without any changes in JV patches or in vena cavae directly sutured [day 14, [Figure 6]a, [Figure 6]b, [Figure 6]c. Control vena cavae showed COUP-TFII immunoreactivity present, without notch-4 and dll-4 immunoreactivity, in endothelial cells, whereas arteries showed notch-4 and dll-4 immunoreactivity in endothelial cells [Figure 6]d, first and second columns]. At day 14, neointimal endothelial cells showed COUP-TFII immunoreactivity with minimal notch-4 and dll-4 immunoreactivity [Figure 6]d; quantification showed similar notch-4, dll-4, and COUP-TFII immunoreactivity in JV and CA patches compared to the native vena cava and directly sutured vena cava [Figure 6]e, [Figure 6]f, [Figure 6]g, that is strong Eph-B4 and COUP-TFII and weak ephrin-B2, notch-4, and dll-4 immunoreactivity in patches used to close a vein, regardless of the source of the patch. These data suggest that venous patches placed into the venous environment retain their venous identity, but arterial patches lose arterial identity and gain venous identity in the venous environment.{Figure 6}

 Discussion



Although prosthetic patches heal by acquisition of environmentally determined vascular identity, the mechanism by which autologous tissue patches heal was not previously described. We show that autologous tissue patches placed into the arterial environment have identifiable arterial endothelial progenitor cells [Figure 1]; arterial-derived patches retain ephrin-B2, notch-4, and dll-4 expression and venous-derived patches acquire this expression pattern [Figure 2] and [Figure 3]. Conversely, autologous tissue patches placed into the venous environment have identifiable venous endothelial progenitor cells [Figure 4]; venous-derived patches retain Eph-B4 and COUP-TFII expression and arterial-derived patches acquire this expression pattern [Figure 5] and [Figure 6]. These data show that autologous tissue patches heal by acquisition of the vascular identity determined by the environment into which they are implanted, suggesting some plasticity of adult vascular identity.

We show that venous patches lose venous identity and gain arterial identity in the arterial environment [Figure 1], [Figure 2], [Figure 3]. Various experiments' similar changes have been shown in vitro as well as in embryos,[18],[19] and we have previously shown loss of venous identity without gain of identity both in vitro[20] and in vivo.[9] Using a mouse cuffed vein graft model, Koga et al. showed that arterial markers were upregulated.[21] We have shown that both venous and arterial markers are expressed in the arteriovenous fistula environment that has some features of the arterial environment.[10],[22] Our finding that autologous venous patches express arterial identity markers in the arterial environment is consistent with these data as well as with our previous data in prosthetic patches.[6],[8] It is possible that regulation of vascular identity depends on environmental features such as shear stress. Endothelial cell ephrin-B2 expression is controlled by microenvironmental determinants,[23] and shear stress stimulates expression of ephrin-B2 in endothelial cells.[24] We have shown increased ephrin-B2 expression in prosthetic patches exposed to increased shear stress.[8],[10] However, our finding that arterial progenitor cells were present [Figure 1] suggests that progenitor cells might play a role in acquisition of identity;[25] it is unknown whether these progenitor cells are infiltrating from the environment or whether they are activated from endogenous vessel cells.

We also show that arterial patches lose arterial identity and gain venous identity in the venous environment [Figure 4], [Figure 5], [Figure 6]. Patches in the venous environment are uncommon but occasionally reported to be used in some oncology resections [26],[27] and living donor liver transplantation;[28] however, arterial patches are generally not performed for venous reconstruction. Nevertheless, our findings complement the findings in the arterial environment and strengthen the possibility that environmental cues such as pressure, shear stress, and oxygen tension are critical for determination of vascular identity.

We also find that macrophages may play a role in the determination of vessel identity, with more M2 type macrophages present than M1 type macrophages at day 14 [Supplemental Figure 2]. We have previously shown that macrophages, and especially M2 type macrophages, are critical for vascular remodeling such as occurs during vein graft adaptation and arteriovenous fistula remodeling.[29],[30] Macrophages play a complicated role in arterial remodeling such as occurs during aneurysm formation.[31],[32] Interestingly, there were more M2 type macrophages in the JV patches compared to the CA patches [Supplemental Figure 2], suggesting a role for macrophages in the developing neointima. However, the relationship between macrophages and development of vascular identity is not clear.

We find that acquisition of vascular identity is dependent on the environment and not dependent on the particular biomaterial. Regulation of vascular identity may be a strategy to improve the outcomes of vascular interventions.

Acknowledgment

This work was supported by US National Institute of Health Grants (R56-HL095498 and R01-HL128406 [to A. D.]); the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program (Merit Review Award I01-BX002336 [to A. D.]); as well as with the resources and the use of facilities at the VA Connecticut Healthcare System, West Haven, CT.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Bond R, Rerkasem K, Naylor AR, Aburahma AF, Rothwell PM. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. J Vasc Surg 2004;40:1126-35.
2Muto A, Nishibe T, Dardik H, Dardik A. Patches for carotid artery endarterectomy: Current materials and prospects. J Vasc Surg 2009;50:206-13.
3Li X, Guo Y, Ziegler KR, Model LS, Eghbalieh SD, Brenes RA, et al. Current usage and future directions for the bovine pericardial patch. Ann Vasc Surg 2011;25:561-8.
4Bai H, Lee JS, Chen E, Wang M, Xing Y, Fahmy TM, et al. Covalent modification of pericardial patches for sustained rapamycin delivery inhibits venous neointimal hyperplasia. Sci Rep 2017;7:40142.
5Bai H, Li X, Hashimoto T, Hu H, Foster TR, Hanisch JJ, et al. Patch angioplasty in the rat aorta or inferior vena cava. J Vis Exp 2017.
6Li X, Jadlowiec C, Guo Y, Protack CD, Ziegler KR, Lv W, et al. Pericardial patch angioplasty heals via an ephrin-B2 and CD34 positive cell mediated mechanism. PLoS One 2012;7:e38844.
7Bai H, Wang M, Foster TR, Hu H, He H, Hashimoto T, et al. Pericardial patch venoplasty heals via attraction of venous progenitor cells. Physiol Rep 2016;4. pii: e12841.
8Bai H, Hu H, Guo J, Ige M, Wang T, Isaji T, et al. Polyester vascular patches acquire arterial or venous identity depending on their environment. J Biomed Mater Res A 2017;105:3422-31.
9Kudo FA, Muto A, Maloney SP, Pimiento JM, Bergaya S, Fitzgerald TN, et al. Venous identity is lost but arterial identity is not gained during vein graft adaptation. Arterioscler Thromb Vasc Biol 2007;27:1562-71.
10Protack CD, Foster TR, Hashimoto T, Yamamoto K, Lee MY, Kraehling JR, et al. Eph-B4 regulates adaptive venous remodeling to improve arteriovenous fistula patency. Sci Rep 2017;7:15386.
11El-Sayed HF. Bypass surgery for lower extremity limb salvage: Vein bypass. Methodist Debakey Cardiovasc J 2012;8:37-42.
12Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, et al. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: One-year graft failure and five-year outcomes from the project of ex vivo vein graft engineering via transfection (PREVENT) IV trial. Circulation 2011;124:280-8.
13Athanasiou T, Saso S, Rao C, Vecht J, Grapsa J, Dunning J, et al. Radial artery versus saphenous vein conduits for coronary artery bypass surgery: Forty years of competition – which conduit offers better patency? A systematic review and meta-analysis. Eur J Cardiothorac Surg 2011;40:208-20.
14Desai ND, Cohen EA, Naylor CD, Fremes SE; Radial Artery Patency Study Investigators. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 2004;351:2302-9.
15Modine T, Al-Ruzzeh S, Mazrani W, Azeem F, Bustami M, Ilsley C, et al. Use of radial artery graft reduces the morbidity of coronary artery bypass graft surgery in patients aged 65 years and older. Ann Thorac Surg 2002;74:1144-7.
16O'Hara PJ, Hertzer NR, Mascha EJ, Krajewski LP, Clair DG, Ouriel K, et al. A prospective, randomized study of saphenous vein patching versus synthetic patching during carotid endarterectomy. J Vasc Surg 2002;35:324-32.
17Jacobowitz GR, Kalish JA, Lee AM, Adelman MA, Riles TS, Landis R, et al. Long-term follow-up of saphenous vein, internal jugular vein, and knitted Dacron patches for carotid artery endarterectomy. Ann Vasc Surg 2001;15:281-7.
18Moyon D, Pardanaud L, Yuan L, Bréant C, Eichmann A. Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. Development 2001;128:3359-70.
19Zhang G, Zhou J, Fan Q, Zheng Z, Zhang F, Liu X, et al. Arterial-venous endothelial cell fate is related to vascular endothelial growth factor and Notch status during human bone mesenchymal stem cell differentiation. FEBS Lett 2008;582:2957-64.
20Model LS, Hall MR, Wong DJ, Muto A, Kondo Y, Ziegler KR, et al. Arterial shear stress reduces eph-b4 expression in adult human veins. Yale J Biol Med 2014;87:359-71.
21Koga JI, Nakano T, Dahlman JE, Figueiredo JL, Zhang H, Decano J, et al. Macrophage notch ligand delta-like 4 promotes vein graft lesion development: Implications for the treatment of vein graft failure. Arterioscler Thromb Vasc Biol 2015;35:2343-53.
22Lu DY, Chen EY, Wong DJ, Yamamoto K, Protack CD, Williams WT, et al. Vein graft adaptation and fistula maturation in the arterial environment. J Surg Res 2014;188:162-73.
23Korff T, Dandekar G, Pfaff D, Füller T, Goettsch W, Morawietz H, et al. Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol 2006;26:468-74.
24Masumura T, Yamamoto K, Shimizu N, Obi S, Ando J. Shear stress increases expression of the arterial endothelial marker ephrinB2 in murine ES cells via the VEGF-Notch signaling pathways. Arterioscler Thromb Vasc Biol 2009;29:2125-31.
25Ohtani-Kaneko R, Sato K, Tsutiya A, Nakagawa Y, Hashizume K, Tazawa H, et al. Characterisation of human induced pluripotent stem cell-derived endothelial cells under shear stress using an easy-to-use microfluidic cell culture system. Biomed Microdevices 2017;19:91.
26Del Campo C, Konok GP. Use of a pericardial xenograft patch in repair of resected retrohepatic vena cava. Can J Surg 1994;37:59-61.
27Ohwada S, Watanuki F, Nakamura S, Kawashima Y, Nakagami K, Ogawa T, et al. Glutaraldehyde-fixed heterologous pericardium for vena cava grafting following hepatectomy. Hepatogastroenterology 1999;46:855-8.
28Mori A, Kaido T, Ogura Y, Ogawa K, Hata K, Yagi S, et al. Standard hepatic vein reconstruction with patch plasty using the native portal vein in adult living donor liver transplantation. Liver Transpl 2012;18:602-7.
29Kondo Y, Jadlowiec CC, Muto A, Yi T, Protack C, Collins MJ, et al. The nogo-B-pirB axis controls macrophage-mediated vascular remodeling. PLoS One 2013;8:e81019.
30Kuwahara G, Hashimoto T, Tsuneki M, Yamamoto K, Assi R, Foster TR, et al. CD44 promotes inflammation and extracellular matrix production during arteriovenous fistula maturation. Arterioscler Thromb Vasc Biol 2017;37:1147-56.
31Nowicki KW, Hosaka K, Walch FJ, Scott EW, Hoh BL. M1 macrophages are required for murine cerebral aneurysm formation. J Neurointerv Surg 2018;10:93-7.
32Dale MA, Xiong W, Carson JS, Suh MK, Karpisek AD, Meisinger TM, et al. Elastin-derived peptides promote abdominal aortic aneurysm formation by modulating M1/M2 macrophage polarization. J Immunol 2016;196:4536-43